The effects of adjuvant therapies for sepsis on hepatic and renal function: A retrospective analysis of 108 ICU patients;Sepsiste uygulanan destek tedavilerin karaciǧer ve böbrek fonksiyonlarına etkisinin deǧerlendirilmesi: Yoǧun bakımda 108 hastanın retrospektif analizi

Turkish Journal of Medical Sciences

Volumn 40, Issue 6, 2010, Pages 949-957

  Ceylan, Berit Gökçe ^a   Yavuz, Lütfi ^a   Eroǧlu, Füsun ^a   Gülmen, Şenol ^a   Tarhan, Ömer Ridvan ^a   Alaca, Adnan ^a  

^a SULEYMAN DEMIREL UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

Activated protein C; Hepatic functions; Intravenous immunoglobulin; Renal functions; Sepsis

Indexed keywords

GLYCOPROTEINS; INTENSIVE CARE UNITS; PATIENT TREATMENT; RECOMBINANT PROTEINS;

ACTIVATED PROTEIN C; HEPATIC FUNCTION; INTRAVENOUS IMMUNOGLOBULIN; RENAL FUNCTIONS; SEPSIS;

FUNCTION EVALUATION;

ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; ANTIBIOTIC AGENT; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CREATININE; DROTRECOGIN; IMMUNOGLOBULIN; NITROGEN; UREA;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; INTENSIVE CARE UNIT; INTERNATIONAL NORMALIZED RATIO; KIDNEY FUNCTION; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; RETROSPECTIVE STUDY; SEPSIS; UREA NITROGEN BLOOD LEVEL; URINE VOLUME;

EID: 79952220565     PISSN: 13000144     EISSN: None     Source Type: Journal    
DOI: 10.3906/sag-0906-58     Document Type: Article

References (24)

1. Schmid A, Burchardi H, Clouth J, Schneider H. Burden of illness imposed by severe sepsis in Germany. Eur J Health Econ 2002; 3: 77-82.
2. Camporota L, Wyncoll D. Practical aspects of treatment with drotrecogin alfa activated. Crit Care 2007; 11 Suppl 5:S7.
3. Issa N, Messer J, Paganini EP. Renal assist device and treatment of sepsis-induced acute kidney injury in intensive care units. Contrib Nephrol 2007; 156: 419-27.
4. Yang S, Cioffi WG, Bland KI, Chaudry IH, Wang P. Differential alterations in systemic and regional oxygen delivery and consumption during the early and late stages of sepsis. J Trauma 1999; 47: 706-712.
5. Jacob A, Zhou M, Wu R, Wang P. The role of hepatic cytochrome P-450 in sepsis. Int J Clin Exp Med 2009 Aug 25; 2: 203-11.
6. Buda S, Riefolo A, Biscione R, Goretti E, Cattabriga I, Grillone G et al. Clinical experience with polyclonal IgM-enriched immunoglobulins in a group of patients affected by sepsis after cardiac surgery. J Cardiothorac Vasc Anesth 2005; 19: 440-5.
7. Reshetnikov EA, Baranov GA, Chuvanov MV, Skalozub OI. Immunotherapy in complex treatment of surgical sepsis. Khirurgiia (Mosk) 2008; 7: 11-4.
8. Azevedo LC, Park M, Schettino GP. Novel potential therapies for septic shock. Shock 2008; 30 Suppl 1: 60-6.
9. Fabrizio K, Groner A, Boes M, Pirofski LA. A human monoclonal immunoglobulin M reduces bacteremia and inflammation in a mouse model of systemic pneumococcal infection. Clin Vaccine Immunol 2007; 14: 382-90.
10. Yi{dotless}ldi{dotless}z BD, Yorganci{dotless} K. Current trends and future implications in sepsis treatment. Turk J Med Sci 2008; 38: 501-10.
11. Rice TW. Treatment of severe sepsis: where next? Current and future treatment approaches after the introduction of drotrecogin alpha. Vasc Health Risk Manag 2006; 2: 3-18.
12. Lehmann C, Meissner K, Knöck A, Diedrich S, Pavlovic D, Gründling M et al. Activated protein C improves intestinal microcirculation in experimental endotoxaemia in the rat. Crit Care 2006; 10: R157.
13. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med 1985; 13: 818-29.
14. Neilson AR, Burchardi H, Schneider H. Cost-effectiveness of immunoglobulin M-enriched immunoglobulin (Pentaglobin) in the treatment of severe sepsis and septic shock. J Crit Care 2005; 20: 239-49.
15. Crouser ED. Mitochondrial dysfunction in septic shock and multiple organ dysfunction syndrome.Mitochondrion 2004; 4: 729-41.
16. Satoi S, Kamiyama Y, Kitade H, Kwon AH, Takahashi K, Wei T et al. Nitric oxide production and hepatic dysfunction in patients with postoperative sepsis. Clin Exp Pharmacol Physiol 2000; 27: 197-201.
17. Strassburg CP. Shock liver. Best Pract Res Clin Gastroenterol 2003; 17: 369-81
18. Ramakers BP, de Goeij M, van der Hoeven JG, Peters WH, Pickkers P. Inflammation-induced hepatotoxicity in humans. Shock 2009; 31: 151-6.
19. Langenberg C, Bellomo R, May C, Wan L, Egi M, Morgera S. Renal blood flow in sepsis. Crit Care 2005; 9: R363-74.
20. Bellomo R, Wan L, Langenberg C, May C. Septic acute kidney injury: new concepts. Nephron Exp Nephrol 2008; 109: 95-100.
21. Gupta A, Gerlitz B, Richardson MA, Bull C, Berg DT, Syed S et al. Distinct Functions of Activated Protein C Differentially Attenuate Acute Kidney Injury. J Am Soc Nephrol 2009; 20: 267-77.
22. Gupta A, Berg DT, Gerlitz B, Sharma GR, Syed S, Richardson MA et al. Role of protein C in renal dysfunction after polymicrobial sepsis. J Am Soc Nephrol 2007; 18: 860-7.
23. Mikaszewska-Sokolewicz M, Nierebińska M, Mayzner-Zawadzka E. Use of drotrecogin alfa (activated) in two patients with severe sepsis. Med Sci Monit 2003; 9: CS80-7.
24. Hoffman JN, Fertmann JM, Vollmar B, Laschke MW, Jauch KW, Menger MD. Immunoglobulin M-enriched human intravenous immunoglobulins reduce leukocyte-endothelial cell interactions and attenuate microvascular perfusion failure in normotensive endotoxemia. Shock 2008; 29: 133-9.